Efficacy and safety of two moisturising creams for maintenance treatment of atopic dermatitis

Prior treatment

• Patients treated for AD with systemic drugs, topical corticosteroids class IV and light treatment during the last 3 months
• Any concomitant medications that, in the opinion of the Investigator, could affect the study outcome

Other illness

• Known sensitivity or allergy to any of the study products
• Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant (e.g., compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments or procedures

Other

• Eczema exclusively on the hands
• Patients assessed by the Investigator to have mild atopic dermatitis
• Patients assessed by the Investigator to have poor compliance
• Patients assessed by the Investigator to have difficulty reading and understanding the local language
• Patients who are pregnant, breast feeding or planning to become pregnant during study participation

• The patient has given their written consent to participate in the study
• Age ≥ 18 years
• Patients with known AD or diagnosed with AD according to the Williams criteria [1] with visible atopic lesions on arms and/or legs. Two lesions on left respective right side with a size of 2 x 2 cm to 10 x 10 cm should be available, i.e., study areas. The largest lesion should not be more than 50% larger than the smallest lesion in length and width, i.e., the length of the largest selected lesion ≤ 1.5× the length of the smallest and the width of the largest selected lesion ≤ 1.5× width of the smallest lesion
• Moderate to severe form of AD, IGA ≥ 3 [2], a mEASI score on the defined study areas of ≥ 4 and with a difference between left study area to right study area of ≤ 1 and which, in the opinion of the Investigator, can achieve complete clearance with a class III corticosteroid treatment for approximately 4 weeks